An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of NCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Parsaclisib (Primary) ; Bendamustine; Obinutuzumab
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms CITADEL-102
- Sponsors Incyte Corporation
- 20 Mar 2019 Planned End Date changed from 1 Mar 2020 to 30 Sep 2021.
- 20 Mar 2019 Planned primary completion date changed from 1 Sep 2019 to 30 Sep 2021.
- 19 Dec 2018 Status changed from recruiting to active, no longer recruiting.